Literature DB >> 18630483

Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.

Jan Styczynski1, Mariusz Wysocki, Agnieszka Dluzniewska, Edyta Juraszewska, Walentyna Balwierz, Krzysztof Czyzewski, Maria Wieczorek, Igor Olejnik, Maryna Krawczuk-Rybak, Marta Kuzmicz, Jerzy Kowalczyk, Jolanta Stefaniak, Wanda Badowska, Danuta Sonta-Jakimczyk, Tomasz Szczepanski, Michal Matysiak, Elzbieta Stanczak, Iwona Malinowska, Jacek Wachowiak, Benigna Konatkowska, Lidia Gil, Anna Balcerska, Lucyna Kapuscinska, Joanna Szczepanek, Beata Kolodziej, Beata Rafinska, Malgorzata Kubicka.   

Abstract

BACKGROUND: The role of cellular drug resistance in childhood acute myeloid leukemia (AML) has not yet been established. The aim of the study was the analysis of the clinical value of ex vivo drug resistance in pediatric AML. PATIENTS AND METHODS: A cohort of 90 children with de novo AML were assayed for drug resistance profile by the 3-4,5-dimethylthiazol-2-yl-2,5-difenyl tetrazolium bromide (MTT) assay and prognostic model of in vitro drug sensitivity was analyzed.
RESULTS: Children who relapsed during follow-up showed higher in vitro resistance of leukemic blasts to most of the drugs tested, except for cytarabine, cladribine, vincristine, mercaptopurine and thioguanine. A combined in vitro drug resistance profile to fludarabine, treosulfan and mitoxantrone (FTM score) was defined and it had an independent prognostic significance for disease free survival in pediatric AML.
CONCLUSION: The combined fludarabine, treosulfan and mitoxantrone resistance profile to possibly may be used for better stratification of children with AML or indicate the necessity for additional therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18630483

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Gene expression signatures and ex vivo drug sensitivity profiles in children with acute lymphoblastic leukemia.

Authors:  Joanna Szczepanek; Michal Jarzab; Malgorzata Oczko-Wojciechowska; Malgorzata Kowalska; Andrzej Tretyn; Olga Haus; Monika Pogorzala; Mariusz Wysocki; Barbara Jarzab; Jan Styczynski
Journal:  J Appl Genet       Date:  2011-10-27       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.